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ABSTRACT
Non-fermenting Gram-negative bacteria are problematic in clinical locations, being one of the most
prevalent causes of nosocomial infections. Many of these non-fermenting Gram-negative bacteria
are opportunistic pathogens that affect patients that are suffering with underlying medical
conditions and diseases. Brevundimonas spp., in particular Brevundimonas diminuta and
Brevundimonas vesicularis, are a genus of non-fermenting Gram-negative bacteria considered of
minor clinical importance. Forty-nine separate instances of infection relating to Brevundimonas spp
were found in the scientiﬁc literature along with two pseudo-infections. The majority of these
instances were infection with Brevundimonas vesicularis (thirty-ﬁve cases – 71%). The major
condition associated with Brevundimonas spp infection was bacteraemia with seventeen individual
cases/outbreaks (35%). This review identiﬁed forty-nine examples of Brevundimonas spp. infections
have been discussed in the literature. These ﬁndings indicate that infection review programs should
consider investigation of possible Brevundimonas spp outbreaks if these bacteria are clinically







Gram-negative, non-fermenting bacteria are an
emerging concern in clinical locations, being a com-
mon cause of nosocomial infections. Opportunistic
pathogens from this group include many different
bacterial species, including: Acinetobacter baumannii,
Burkholderia cepacia, Ralstonia pickettii, Pseudomonas
aeruginosa, Sphingomonas pauciomobilis, and Steno-
trophomonas maltophilia [1–8]. The group can sur-
vive in a wide variety of environments including
different water sources (aircraft water, bottled water,
hospital water, puriﬁed water) [9–12], and are usually
resistant to a wide array of antimicrobials [13,14].
Examples include resistance to penicillins, aminogly-
cosides and monobactems in R. pickettii [13] and
penicillins, aminoglycosides, carbapenems and mono-
bactems in S. maltophilia [14]. Bacteria such as these
have the ability to infect patients/individuals with
underlying medical conditions and diseases. Examina-
tion of the scientiﬁc literature showed multiple types
of infections resulting from Brevundimonas spp. This
indicates that the genus may be a more widespread
pathogen than was hitherto thought, with infections
caused by Brevundimonas spp. being invasive and
severe. The goal of this study was to give an overview
of the range of Brevundimonas spp infections, any
underlying conditions associated with Brevundimonas
spp infections and the treatment options used in the
treatment of any Brevundimonas spp infections in
order to assist medical practitioners.
Genus Brevundimonas
The genus Brevundimonas was ﬁrst proposed by Segers
et al [15]; incorporating Pseudomonas diminuta and
Pseudomonas vesicularis [16,17]. Several species of the
genus Caulobacter were later transferred to Brevundimo-
nas signiﬁcantly emending the description of the genus
[18]. Currently, there are 25 species with valid published
names within the Brevundimonas genus (http://www.bac
terio.net/brevundimonas.html). The type species is Bre-
vundimonas diminuta; with the type strain being LMG
2089.
Brevundimonas species are aerobic Gram-negative,
oxidase and catalase positive, non-fermenting rods 1
to 4 mm in length and 0.5 mm in width, belonging to
the Alphaproteobacteria class and Caulobacteraceae
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family with a DNA G + C content of 65% to 68%
[15]. Motility is provided by one short polar ﬂagel-
lum. Brevundimonas spp. have been isolated from
multiple environments, including soils [9–21], deep
subsea ﬂoor sediment [22] activated sludge,[23] black
sand, [24], deep subsea ﬂoor sediment [25] numerous
aquatic habitats [26], puriﬁed water [27] and also




Brevundimonas diminuta is the type species of
the Brevundimonas genus. It has been isolated from
clinical specimens, including blood and urine [15] as
well as from the lung sputum of cystic ﬁbrosis patients
[29]. B. diminuta is not believed to be a signiﬁcant
pathogen and its virulence is generally low. B. dimin-
uta is used as a test organism to validate reverse-
osmosis (RO) ﬁltration devices for drinking water
puriﬁcation and is also used to test the porosity of
pharmaceutical-grade ﬁlters (0.2 mm) due to the small
size of the bacterium when grown in minimal media
[30,31]. The bacterium has however been shown to be
capable of penetrating these ﬁlters [32]. The bacterium
has been used as a potential bioremediator of marine
oil pollution including diesels, n-alkanes and polycy-
clic aromatic hydrocarbons [33,34] and insecticides
[35]. B. diminuta has also been used to mitigate the
toxic effects of heavy metals on plant growth (rice) in
contaminated soils [36]. B. diminuta also possesses the
ability to survive sanitizers such as Hydrogen Peroxide
+ Peracetic Acid [37]. All available reported incidences
of infection credited to B. diminuta are listed in
Table 1-3.
Brevundimonas vesicularis
Brevundimonas vesicularis has been isolated from eye,
urine, wound cultures, the central nervous system, cer-
vical specimens [38], and also been found in the lung
sputum of cystic ﬁbrosis patients [39]. The organism
has been shown to support the growth of Legionella in
nutrient limited water conditions [40]. The mechanism
behind this phenomenon has not been elucidated but it
is hypothesised to be due to cryptic growth, with B.
vesicularis having the ability to grow in nutrient limited
conditions and Legionella growing on this [40]. Further
research is required to gain a fuller understanding of
this phenomenon. B. vesicularis has been used as a
potential bioremediator of polyaromatic hydrocarbons
[41]. All reported incidences of infection credited to B.
vesicularis are listed in Table 1–3.
Identiﬁcation of Brevundimonas spp
Members of the Brevundimonas spp. are Gram negative
with cells appearing as straight slim rods upon Gram
staining. They are non-spore forming. They are aerobic
with optimal growth temperatures of between 30–37C.
They are oxidase positive and give variable results for
catalase (usually positive). B. diminuta colonies have a
chalk white appearance on MacConkey agar, whereas B.
vesicularis colonies have an orange colour given by an
intracellular pigment. Both grow slowly on ordinary
nutrient media [42]. Both B. vesicularis and B. diminuta
can be identiﬁed via commercial biochemical identiﬁca-
tion kits or systems such as the API 20 NE system, the
VITEK 2 system (bioMerieux) or the Phoenix-100 auto-
mated system (Becton Dickinson). MALDI-TOF identiﬁ-
cation is also being used for identiﬁcation of
Brevundimonas spp. in clinical situations [43,44]. Species
speciﬁc Real Time PCR primers and Fluorescence in situ
hybridization (FISH) probes have been designed for B.
diminuta [45]. These can be seen in Table 4.
Factors associated with Infection
Underlying causes
The majority of infections with Brevundimonas (Table 1–
3) were found to have an underlying condition or disease
that allowed patients to succumb to Brevundimonas
infection. Seven patients, who were suffering with vari-
ous types of cancer, contracted Brevundimonas -related
bacteraemia, Urinary Tract Infection (UTI) and Empy-
ema [46]; a 56-year-old female with Lupus glomerulone-
phritis acquired a Brevundimonas -related leg ulcer [47]
and an infant suffering from Pompe disease was diag-
nosed with Brevundimonas -related bacteraemia [48].
Other examples of patients infected with Brevundimonas
having underlying conditions are shown in Table 1–3.
Such examples demonstrate the role of Brevundimonas
as an opportunistic pathogen in immunocompromised
individuals. Many of these instances of infection were
hospital acquired although a large number were commu-
nity acquired, which is interesting as opportunistic
pathogens such as Brevundimonas spp or R. pickettii are
usually contracted in hospital settings [7].
Co-Infection
Reports of cases of co-infection with Brevundimonas spp





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(one individual case and four cases as part of an out-
break) of co-infection being described in the literature.
Han et al described seven cases of infection with B.
diminuta within the same outbreak, four of these cases
had other microorganism’s co-isolated (coagulase-nega-
tive Staphylococcus – bacteraemia, Moraxella osloensis –
catheter, Enterococcus sp. – UTI and Staphylococcus
aureus – empyema) [46]. Gupta et al. found co-infection
(in a UTI) of B. vesicularis along with Candida tropiclis
and Acinetobacter spp. [49].
Pseudo-outbreaks
As can be seen in Table 5 to date only two pseudo-out-
breaks have been reported with Brevundimonas spp.
Pseudo-outbreaks can be problematic as they can result
in superﬂuous treatments given to patients (e.g. unneces-
sary antibiotics or the removal of indwelling devices such
as catheters) and can waste valuable time and resources
in the clinical setting. The causes of pseudo-outbreaks
may be due to a number of different factors such as con-
taminated water used in the bacterial testing procedures
or contamination of materials used in laboratory testing.
Kim et al [50] described how B. diminuta was the cause
of a pseudo-outbreak in a general hospital ward in South
Korea. Patients did not display symptoms associated
with bacterial infection, even though the organism was
detected. The source of the B. diminuta contamination
was not discovered. Lee et al. [51]. described B. diminuta
as the cause of pseudo-outbreak in a tertiary care centre
in the USA. The contamination was traced to pre-pre-
pared inoculant media (used in the testing procedures
for bacterial detection).
Treatment
The treatment of Brevundimonas spp. infections is fre-
quently difﬁcult, as these bacteria can be resistant to many
different antibiotics including b-lactams and ﬂuoroquino-
lones [46,47]. There have been no controlled trials of anti-
microbial therapy for Brevundimonas spp. infections in
humans therefore therapy should be informed by the
results of in vitro susceptibility testing on isolates. In the
majority of cases listed in Table 1–3 cephalosporins, peni-
cillins or aminoglycoside antibiotics were given to treat
patients and these were mostly successful.
Little is known about resistance mechanisms in Bre-
vundimonas spp. Resistance to the ﬂuoroquinolone fam-
ily of antibiotics has been detected in outbreaks due to
mutations in the quinolone resistance-determining
region (QRDR) of the host gyrA, gyrB and parC genes
[46]. BlaVIM-2 and BlaVIM-13, which mediate resistance to
almost all b-lactams (except aztreonam), have been
found in both environmental and clinical isolates of B.
diminuta [47]. The presence of BlaVIM-2 is related to a
Tn1721-class 1 integron which was discovered in all B.
diminuta isolates, with the determinant located on a
plasmid [47]. This integron also had an aac (6 0)-Ib gene,
which mediates resistance to aminoglycoside antibiotics.
Tetracycline resistance genes have also been found in
environmental isolates of B. diminuta [52].
Breakdown of cases of infection with
Brevundimonas spp.
Literature searches presented in Table 1–3 illustrate 49
separate instances of infection relating to Brevundimonas
spp. The majority of these instances were infection with
B. vesicularis (thirty-ﬁve cases – 71%). One outbreak had
both B. vesicularis and B. diminuta and one case of infec-
tion with B. vancanneytii was reported. The rest of the
cases were made up B. diminuta infections (twelve cases-
24%). The major breakdown of condition were as fol-
lows: seventeen instances of bacteraemia (34%), ﬁve
instances of septicaemia/sepsis (10%), three instances of
pneumonia/ pleuritis (6%), two instances each endocar-
ditis (4%), keratitis (4%), and urinary tract infection
(4%). Serious infections with Brevundimonas spp include
four instances of septicaemia (8%), two of endocarditis
(4%), one of septic arthritis (2%) and one of meningitis
(2%). Other conditions include instances of two cases of
Table 4. Molecular methods applied to identify Brevundimonas spp. [45].
Method Target Sequence Species













FISH gyrB AAGAAGCACAGCGTCCGCTTCGAGC Brevundimonas diminuta
FISH rpoD TCAAGGCCTATTTCGGCTCGGAGAT Brevundimonas diminuta




























































































































































































































































































































































tonsillitis (2%), two of liver abscess (2%) and two of
botryomycosis (2%). There have also been two reported
instances (4%) of Brevundimonas spp infection that have
caused two or more conditions: bacteraemia and reactive
arthritis and bacteraemia, urinary tract infection and
empyema. Four instances of death have been related to
Brevundimonas spp infection, three of bacteraemia and
one of septicaemia.
Conclusions
Brevundimonas spp. are not currently considered as
major pathogens. However, this should be re-evaluated
in light of our investigations where forty-nine examples
of Brevundimonas spp. infections have been found in the
literature. These species have characteristics, such as abil-
ity to pass through sterilising ﬁlters, which may allow
them to cause potentially harmful infections and even
death on occasion. Although it is of low virulence and
not as big a risk as other non-fermenting Gram-negative
bacteria such as Burkholderia etc., it should not be over
looked as a possible cause of nosocomial infections and
should be considered for inclusion in hospital screening
and prevention programs. These programs should con-
sider investigation of possible Brevundimonas spp out-
breaks if these bacteria are clinically isolated in more
than one patient.
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